Koneksa Health is a technology company.
Koneksa Health has raised $45.0M across 1 funding round.
Koneksa Health has raised $45.0M in total across 1 funding round.
Koneksa Health has raised $45.0M in total across 1 funding round.
Koneksa Health's investors include 4BIO Capital, Takeda Ventures.
Koneksa Health is a healthcare technology company founded in 2013 that accelerates drug development by generating multimodal clinical data through remote clinical trials, digital biomarkers, and AI-powered insights.[1][3] It builds a proprietary SaaS platform integrating wearables, mobile tech, patient diaries, ePROs, and traditional endpoints like lab tests and imaging to enable patient-centric, real-world data collection across therapeutic areas, serving biopharma sponsors, clinical sites, payers, and patients to optimize trial design, reduce patient numbers needed, and speed evidence generation.[1][2][4] The company solves core challenges in clinical research—such as infrequent data capture, high costs, and limited insights—by delivering validated digital endpoints, end-to-end study support, data science services, and flexible licensing models, with demonstrated growth through office expansions, partnerships, and integration of new devices like EEG for sleep and neurologic disorders.[3][5][7][8]
Koneksa Health was founded in 2013 as a pioneer in digital biomarkers, initially focusing on designing and executing digital clinical trials to prove the value of remote data collection.[1][3] The company emerged from the need to leverage real-world data from wearables and devices—like blood pressure cuffs, heart rate patches, and spirometers—to enhance clinical evidence without relying solely on in-clinic visits, as highlighted in early presentations like MongoDB World 2017 by its engineering team.[6] Key early traction included rapid growth prompting a 2019 headquarters move to New York’s Financial District, plus teams in Boston, Philadelphia, San Francisco, and London, alongside investments in a hardware testing lab to validate new devices quickly.[4][5] Leadership figures like CEO Chris Benko, Head of Tech R&D Rob Ellis, President and COO Vik Shah, and Chief Medical Officer John Wagner, MD, PhD, have driven evolution from biomarker validation to a full platform supporting multimodal datasets and AI/ML analytics.[5][7][8]
Koneksa rides the wave of digital health transformation in clinical trials, where remote monitoring, wearables, and AI address longstanding inefficiencies like patient burden, data sparsity, and slow drug approvals amid rising biopharma R&D costs.[1][4] Timing aligns with regulatory acceptance of digital endpoints (e.g., FDA pilots) and post-pandemic shifts to decentralized trials, amplified by exploding wearable adoption and real-world evidence demands from payers.[3][6] Market forces favoring Koneksa include biopharma's push for precision medicine in neurology, sleep disorders, and beyond, plus partnerships expanding biomarker scalability.[7][8] It influences the ecosystem by standardizing high-quality digital data integration, enabling sponsors to stratify patients, monitor efficacy remotely, and accelerate therapies—potentially cutting trial timelines and costs while humanizing research.[2][8]
Koneksa is poised to expand its platform with more modalities (e.g., additional EEG, sensors) and therapeutic areas, deepening AI-driven predictive models and partnerships to dominate digital evidence generation.[1][8] Trends like AI regulatory harmonization, multimodal data explosion, and value-based care will propel growth, potentially through acquisitions or IPO as biopharma digitizes trials en masse. Its influence may evolve from biomarker pioneer to indispensable infrastructure, redefining how therapies reach patients faster—echoing its founding mission to unlock clinical insights digitally, remotely, and intelligently.[2][3]
Koneksa Health has raised $45.0M across 1 funding round. Most recently, it raised $45.0M Series C in February 2022.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Feb 1, 2022 | $45.0M Series C | 4BIO Capital, Takeda Ventures |